NCCN 8th Annual Congress: Hematologic Malignancies™
Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This Congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.
Andrew D. Zelenetz, MD, PhD
Memorial Sloan-Kettering Cancer Center
This congress is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
This congress is approved for AMA PRA Category 1 Credit(s)™ for physicians and is also accredited for nurses and pharmacists (ACPE). View complete accreditation details
- 9.50 Participation
- 8.07 Nurse
- 9.50 Pharmacist
- 9.50 Physician